NCAM1 and cancer: In individuals with hematopoietic malignancies who receive hematopoietic stem cell transplants, the functional mature CD3+CD56+ NKT-like cells may produce cytotoxicity against cancer cells and play a therapeutic role against hematopoietic malignancy [13].